---
title: "AstraZeneca's treatment for fatal myocardial disease has been approved for clinical trials in China."
description: "Astrazeneca's new drug ALXN2220 injection has obtained clinical trial implied consent in China for the treatment of diagnosed transthyretin amyloid cardiomyopathy in adult patients. ALXN2220 is a mono"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/109921524.md"
published_at: "2024-03-14T08:07:03.000Z"
---

# AstraZeneca's treatment for fatal myocardial disease has been approved for clinical trials in China.

> Astrazeneca's new drug ALXN2220 injection has obtained clinical trial implied consent in China for the treatment of diagnosed transthyretin amyloid cardiomyopathy in adult patients. ALXN2220 is a monoclonal antibody against transthyretin amyloid protein, with the potential to treat late-stage ATTR-CM patients. Alexion, a subsidiary of Astrazeneca, holds the global exclusive licensing rights for this product. The safety and efficacy of the product have been validated in preclinical models and Phase 1 clinical studies. Currently, Alexion is conducting an international multicenter Phase 3 clinical trial to evaluate the efficacy and safety of ALXN2220.

Zhitong App learned recently that the China National Medical Products Administration's Drug Evaluation Center website announced that Astrazeneca's Class 1 new drug ALXN2220 injection has obtained implied approval for clinical trials, intended for the treatment of **clinically diagnosed wild-type or hereditary transthyretin amyloidosis in adult patients**.

ALXN2220 is **a monoclonal antibody against transthyretin amyloid (ATTR), serving as an ATTR "depletor."** Alexion, a subsidiary of Astrazeneca focusing on rare diseases, previously secured a **over $700 million collaboration** to gain global exclusive rights for the development, production, and commercialization of this product. This product specifically targets misfolded transthyretin protein, clearing amyloid fibril deposits in the heart, addressing the pathological cause of ATTR-CM, with the potential to treat late-stage ATTR-CM patients. **Preclinical models have shown that this product can induce the clearance of pathological ATTR**.

In June 2023, the Phase 1 clinical study of ALXN2220 for treating ATTR-CM was published in the New England Journal of Medicine. The results indicated that the safety of ALXN2220 remained good even at the highest test dose, with no significant dose-limiting toxicity or drug-related severe adverse reactions observed. The pharmacokinetic characteristics of this product are consistent with IgG antibodies, and no drug-resistant antibodies were detected. **At a dose of at least 10mg/kg, the deposition of cardiac amyloid protein in patients (detected by scintigraphy or cardiac MRI) significantly decreased within 12 months.** Biomarkers for measuring cardiac pressure and myocardial cell death, **NT-proBNP and troponin T levels, also decreased**.

According to the ClinicalTrials website, Alexion has registered an international multicenter (including China) Phase 3 clinical study (DepleTTR-CM study) to evaluate the efficacy and safety of ALXN2220 compared to a placebo in treating adult patients with ATTR-CM. This study plans to enroll 1000 participants, with an expected completion date in **June 2028**.

### Related Stocks

- [AZN.UK - AstraZeneca PLC](https://longbridge.com/en/quote/AZN.UK.md)
- [ALX.US - Alexanders](https://longbridge.com/en/quote/ALX.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 康斯托克资源｜10-K：2025 财年营收 22.2 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276369088.md) |
| 中国环球资产管理有限公司持有价值 1025 万美元的阿斯利康股份 $AZN | 中国泛华资产管理有限公司在第三季度减少了对阿斯利康制药的持股比例，下降了 10.4%，目前持有 133,580 股，市值为 1025 万美元。这使得阿斯利康占其总持股的 0.8%。其他对冲基金也调整了他们的持仓，几家显著增加了他们的持股比例 | [Link](https://longbridge.com/en/news/276435119.md) |
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 阿斯利康称，美国 FDA 已批准 Calquence 组合疗法用于特定血癌患者 | 阿斯利康表示，美国 FDA 批准 Calquence 联合疗法用于某些血癌患者 | [Link](https://longbridge.com/en/news/276444179.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
